Gilead Sciences (GILD) Given Coverage Optimism Score of 0.14

Share

Kayne Anderson Capital Advisors Lp who had been investing in Ares Cap Corp for a number of months, seems to be less bullish one the $6.99B market cap company.

Price-to-Earnings Ratio is the current share price divided by annual earnings per share. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Northern Capital Management LLC's holdings in Gilead Sciences were worth $1,292,000 as of its most recent SEC filing. Letko Brosseau & Associates Inc acquired 10,477 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%. The Boston Advisors Llc holds 390,220 shares with $27.62M value, down from 506,425 last quarter.

The market capitalization of Gilead Sciences Inc.is at $94.61 Billion.

Sikh body slams Dyal Singh move
"Notification was issued that Executive Council approved Dyal Singh evening college becoming a full-fledged day college". A group of teachers and students had allegedly tried to disrupt a governing body meeting to be held that day.

Shares of Gilead Sciences (GILD) traded down $0.37 during mid-day trading on Monday, reaching $72.07. Shares of GILD have sank -0.22% in the past three monthswhile the S&P 500 has dropped -5.51% in that time. Comparatively, Gilead Sciences Inc. posted earnings of $2.7 per share in the same quarter a year ago. It has underperformed by 38.50% the S&P500.

The stock increased 0.21% or $0.11 on November 17, reaching $51.65. About 623,765 shares traded. It has outperformed by 45.33% the S&P500. They expect $-0.75 EPS, up 35.34% or $0.41 from last year's $-1.16 per share. Finally, Principal Financial Group Inc. increased its stake in shares of Gilead Sciences by 41.2% during the second quarter. The Gilman Hill Asset Management Llc holds 180,707 shares with $4.36M value, up from 158,501 last quarter. Moreover, Aisling Capital Llc has 1.99% invested in the company for 482,680 shares. The institutional investor owned 18,255 shares of the biopharmaceutical company's stock after selling 8,110 shares during the period. Hightower Advisors Limited, a Illinois-based fund reported 361,660 shares. It also reduced Intel Corp (NASDAQ:INTC) stake by 74,060 shares and now owns 3.29M shares. Jones Lang Lasalle Inc (NYSE:JLL) was reduced too. BidaskClub cut Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Wednesday, August 9th. Therefore 32% are positive. Argus upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $100.00 price objective on the stock in a research report on Thursday, August 31st. The firm has "Hold" rating given on Tuesday, November 14 by BMO Capital Markets. The firm earned "Hold" rating on Tuesday, March 15 by Jefferies. Long Road Investment Counsel Limited Company holds 1.47% in Gilead Sciences, Inc. (NASDAQ:GILD) has "Buy" rating given on Wednesday, October 4 by RBC Capital Markets. On Monday, July 24 the stock rating was maintained by J.P. Morgan with "Buy". The stock of Ares Capital Corporation (NASDAQ:ARCC) has "Buy" rating given on Thursday, November 2 by Jefferies. Barclays Capital maintained it with "Overweight" rating and $46 target in Monday, September 26 report. The firm earned "Buy" rating on Wednesday, October 4 by RBC Capital Markets. On Wednesday, June 14 the stock rating was maintained by William Blair with "Buy". (NASDAQ:GILD) news were published by: Seekingalpha.com which released: "Gilead: A Buy After Earnings" on October 27, 2017, also Seekingalpha.com with their article: "Watch Out Gilead, Juno's Strategy Might Just Pay Off" published on November 16, 2017, Seekingalpha.com published: "Gilead Is Persona Non Grata" on November 01, 2017. During the same quarter in the previous year, the business earned $2.75 earnings per share. 73,333 shares were sold by MARTIN JOHN C, worth $4.78M. Alton Gregg H also sold $325,114 worth of Gilead Sciences, Inc. (NASDAQ:OESX) has "Buy" rating given on Monday, July 18 by Rodman & Renshaw. Investors of record on Friday, December 15th will be paid a dividend of $0.52 per share. Its up 0.02, from 0.91 in 2017Q1. It is negative, as 8 investors sold Orion Energy Systems, Inc. shares while 9 reduced holdings. 110 funds opened positions while 462 raised stakes. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts' consensus estimates of $2.13 by $0.14. After $0.82 actual earnings per share reported by D. R. Horton Inc for the previous quarter, Wall Street now forecasts -29.27% negative EPS growth.

Gilead Sciences Inc. (GILD) is expected to post revenue of $5.69 Billion in the current quarter, according to consensus of 19 analysts. (NASDAQ:GILD) for 22,613 shares. 13,686 were accumulated by Horizon Ltd Co. Mckinley Capital Ltd Limited Liability Company Delaware has invested 0.03% of its portfolio in Capstead Mortgage Corporation (NYSE:CMO). (NASDAQ:GILD) or 16.43 million shares. Neuberger Berman Gp Limited Liability invested in 0.23% or 2.58 million shares. Indiana Trust & Invest holds 0.45% or 12,955 shares in its portfolio. Mutual Federation Of Agricultural Cooperatives has invested 0.03% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Smith Salley And owns 24,281 shares or 0.35% of their USA portfolio. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) for 963,721 shares. Sanders Capital Llc, a New York-based fund reported 19.76 million shares. 5 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. Reilly Advsrs Ltd Liability Company holds 0.01% of its portfolio in Gilead Sciences, Inc. Baystate Wealth Mngmt Limited Liability Corp has 0.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Majedie Asset Management has 102,060 shares for 0.68% of their portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Share